Influencing factors on the safety and effectiveness of venom immunotherapy

Objectives: The safety profile of venom immunotherapy (VIT) is a relevant issue and considerable differences in safety and efficacy of VIT have been reported. The primary aim of this study was to evaluate the safety of ACE inhibitors and beta-blockers during VIT, which has already been published. Fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of investigational allergology & clinical immunology 2023-11, Vol.35 (1), p.0-0
Hauptverfasser: Arzt-Gradwohl, L, Annik Herzog, S, Aberer, W, Alfaya Arias, T, Antolín-Amérigo, D, Bonadonna, P, Boni, E, Bożek, A, Chełmińska, M, Ernst, B, Frelih, N, Gawlik, R, Gelincik, A, Hawranek, T, Hoetzenecker, W, Jiménez Blanco, A, Kita, K, Kendirlinan, R, Košnik, M, Laipold, K, Lang, R, Marchi, F, Mauro, M, Nittner-Marszalska, M, Poziomkowska-Gęsicka, I, Pravettoni, V, Preziosi, D, Quercia, O, Reider, N, Rosiek-Biegus, M, Ruiz-Leon, B, Schrautzer, C, Serrano, P, Sin, A, Ayşe Sin, B, Stoevesandt, J, Trautmann, A, Vachová, M, Johannes Sturm, G
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 0
container_issue 1
container_start_page 0
container_title Journal of investigational allergology & clinical immunology
container_volume 35
creator Arzt-Gradwohl, L
Annik Herzog, S
Aberer, W
Alfaya Arias, T
Antolín-Amérigo, D
Bonadonna, P
Boni, E
Bożek, A
Chełmińska, M
Ernst, B
Frelih, N
Gawlik, R
Gelincik, A
Hawranek, T
Hoetzenecker, W
Jiménez Blanco, A
Kita, K
Kendirlinan, R
Košnik, M
Laipold, K
Lang, R
Marchi, F
Mauro, M
Nittner-Marszalska, M
Poziomkowska-Gęsicka, I
Pravettoni, V
Preziosi, D
Quercia, O
Reider, N
Rosiek-Biegus, M
Ruiz-Leon, B
Schrautzer, C
Serrano, P
Sin, A
Ayşe Sin, B
Stoevesandt, J
Trautmann, A
Vachová, M
Johannes Sturm, G
description Objectives: The safety profile of venom immunotherapy (VIT) is a relevant issue and considerable differences in safety and efficacy of VIT have been reported. The primary aim of this study was to evaluate the safety of ACE inhibitors and beta-blockers during VIT, which has already been published. For a second analysis, data concerning premedication and venom preparations in relation to systemic adverse events (AE) during the up-dosing phase and the first year of the maintenance phase were evaluated as well as the outcome of field stings and sting challenges. Methods: The study was conducted as an open, prospective, observational, multicenter study. In total, 1,425 patients were enrolled and VIT was performed in 1,342 patients. Results: Premedication with oral antihistamines was taken by 52.1% of patients during the up-dosing and 19.7% of patients during the maintenance phase. Taking antihistamines had no effect on the frequency of systemic AE (p=0.11) but large local reactions (LLR) were less frequently seen (OR: 0.74; 95% CI: 0.58-0.96; p=0.02). Aqueous preparations were preferentially used for up-dosing (73.0%) and depot preparations for the maintenance phase (64.5%). The type of venom preparation neither had an influence on the frequency of systemic AE nor on the effectiveness of VIT (p=0.26 and p=0.80, respectively), while LLR were less frequently seen when depot preparations were used (p
doi_str_mv 10.18176/jiaci.0967
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2887475932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2887475932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1067-b415c06b29f8d76a1f9900183e391177665815b149a991af434d8c74bd861fdf3</originalsourceid><addsrcrecordid>eNotkEtLxDAUhbNQcBxd-QeyFKRjbtPmsZTBx8iAG12HNE00Q5vUpBX6760zru6B-3E4fAjdANmAAM7uD14bvyGS8TO0AgKikISJC3SZ84EQypngK_S6C66bbDA-fGKnzRhTxjHg8cvirJ0dZ6xDi61z1oz-xwabl7_DS4o99n0_hbiwSQ_zFTp3usv2-v-u0cfT4_v2pdi_Pe-2D_vCAGG8aCqoDWFNKZ1oOdPgpCTLOmqpBOCcsVpA3UAltZSgXUWrVhheNa1g4FpH1-j21Duk-D3ZPKreZ2O7Tgcbp6xKIXjFa0nLBb07oSbFnJN1aki-12lWQNTRkjpaUn-W6C9PeV0V</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2887475932</pqid></control><display><type>article</type><title>Influencing factors on the safety and effectiveness of venom immunotherapy</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Arzt-Gradwohl, L ; Annik Herzog, S ; Aberer, W ; Alfaya Arias, T ; Antolín-Amérigo, D ; Bonadonna, P ; Boni, E ; Bożek, A ; Chełmińska, M ; Ernst, B ; Frelih, N ; Gawlik, R ; Gelincik, A ; Hawranek, T ; Hoetzenecker, W ; Jiménez Blanco, A ; Kita, K ; Kendirlinan, R ; Košnik, M ; Laipold, K ; Lang, R ; Marchi, F ; Mauro, M ; Nittner-Marszalska, M ; Poziomkowska-Gęsicka, I ; Pravettoni, V ; Preziosi, D ; Quercia, O ; Reider, N ; Rosiek-Biegus, M ; Ruiz-Leon, B ; Schrautzer, C ; Serrano, P ; Sin, A ; Ayşe Sin, B ; Stoevesandt, J ; Trautmann, A ; Vachová, M ; Johannes Sturm, G</creator><creatorcontrib>Arzt-Gradwohl, L ; Annik Herzog, S ; Aberer, W ; Alfaya Arias, T ; Antolín-Amérigo, D ; Bonadonna, P ; Boni, E ; Bożek, A ; Chełmińska, M ; Ernst, B ; Frelih, N ; Gawlik, R ; Gelincik, A ; Hawranek, T ; Hoetzenecker, W ; Jiménez Blanco, A ; Kita, K ; Kendirlinan, R ; Košnik, M ; Laipold, K ; Lang, R ; Marchi, F ; Mauro, M ; Nittner-Marszalska, M ; Poziomkowska-Gęsicka, I ; Pravettoni, V ; Preziosi, D ; Quercia, O ; Reider, N ; Rosiek-Biegus, M ; Ruiz-Leon, B ; Schrautzer, C ; Serrano, P ; Sin, A ; Ayşe Sin, B ; Stoevesandt, J ; Trautmann, A ; Vachová, M ; Johannes Sturm, G</creatorcontrib><description>Objectives: The safety profile of venom immunotherapy (VIT) is a relevant issue and considerable differences in safety and efficacy of VIT have been reported. The primary aim of this study was to evaluate the safety of ACE inhibitors and beta-blockers during VIT, which has already been published. For a second analysis, data concerning premedication and venom preparations in relation to systemic adverse events (AE) during the up-dosing phase and the first year of the maintenance phase were evaluated as well as the outcome of field stings and sting challenges. Methods: The study was conducted as an open, prospective, observational, multicenter study. In total, 1,425 patients were enrolled and VIT was performed in 1,342 patients. Results: Premedication with oral antihistamines was taken by 52.1% of patients during the up-dosing and 19.7% of patients during the maintenance phase. Taking antihistamines had no effect on the frequency of systemic AE (p=0.11) but large local reactions (LLR) were less frequently seen (OR: 0.74; 95% CI: 0.58-0.96; p=0.02). Aqueous preparations were preferentially used for up-dosing (73.0%) and depot preparations for the maintenance phase (64.5%). The type of venom preparation neither had an influence on the frequency of systemic AE nor on the effectiveness of VIT (p=0.26 and p=0.80, respectively), while LLR were less frequently seen when depot preparations were used (p&lt;0.001). Conclusions: Pretreatment with oral antihistamines during VIT significantly reduces the frequency of LLR but not systemic AE. All venom preparations used were equally effective and did not differ in the frequency of systemic AE.</description><identifier>ISSN: 1018-9068</identifier><identifier>DOI: 10.18176/jiaci.0967</identifier><language>eng</language><ispartof>Journal of investigational allergology &amp; clinical immunology, 2023-11, Vol.35 (1), p.0-0</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Arzt-Gradwohl, L</creatorcontrib><creatorcontrib>Annik Herzog, S</creatorcontrib><creatorcontrib>Aberer, W</creatorcontrib><creatorcontrib>Alfaya Arias, T</creatorcontrib><creatorcontrib>Antolín-Amérigo, D</creatorcontrib><creatorcontrib>Bonadonna, P</creatorcontrib><creatorcontrib>Boni, E</creatorcontrib><creatorcontrib>Bożek, A</creatorcontrib><creatorcontrib>Chełmińska, M</creatorcontrib><creatorcontrib>Ernst, B</creatorcontrib><creatorcontrib>Frelih, N</creatorcontrib><creatorcontrib>Gawlik, R</creatorcontrib><creatorcontrib>Gelincik, A</creatorcontrib><creatorcontrib>Hawranek, T</creatorcontrib><creatorcontrib>Hoetzenecker, W</creatorcontrib><creatorcontrib>Jiménez Blanco, A</creatorcontrib><creatorcontrib>Kita, K</creatorcontrib><creatorcontrib>Kendirlinan, R</creatorcontrib><creatorcontrib>Košnik, M</creatorcontrib><creatorcontrib>Laipold, K</creatorcontrib><creatorcontrib>Lang, R</creatorcontrib><creatorcontrib>Marchi, F</creatorcontrib><creatorcontrib>Mauro, M</creatorcontrib><creatorcontrib>Nittner-Marszalska, M</creatorcontrib><creatorcontrib>Poziomkowska-Gęsicka, I</creatorcontrib><creatorcontrib>Pravettoni, V</creatorcontrib><creatorcontrib>Preziosi, D</creatorcontrib><creatorcontrib>Quercia, O</creatorcontrib><creatorcontrib>Reider, N</creatorcontrib><creatorcontrib>Rosiek-Biegus, M</creatorcontrib><creatorcontrib>Ruiz-Leon, B</creatorcontrib><creatorcontrib>Schrautzer, C</creatorcontrib><creatorcontrib>Serrano, P</creatorcontrib><creatorcontrib>Sin, A</creatorcontrib><creatorcontrib>Ayşe Sin, B</creatorcontrib><creatorcontrib>Stoevesandt, J</creatorcontrib><creatorcontrib>Trautmann, A</creatorcontrib><creatorcontrib>Vachová, M</creatorcontrib><creatorcontrib>Johannes Sturm, G</creatorcontrib><title>Influencing factors on the safety and effectiveness of venom immunotherapy</title><title>Journal of investigational allergology &amp; clinical immunology</title><description>Objectives: The safety profile of venom immunotherapy (VIT) is a relevant issue and considerable differences in safety and efficacy of VIT have been reported. The primary aim of this study was to evaluate the safety of ACE inhibitors and beta-blockers during VIT, which has already been published. For a second analysis, data concerning premedication and venom preparations in relation to systemic adverse events (AE) during the up-dosing phase and the first year of the maintenance phase were evaluated as well as the outcome of field stings and sting challenges. Methods: The study was conducted as an open, prospective, observational, multicenter study. In total, 1,425 patients were enrolled and VIT was performed in 1,342 patients. Results: Premedication with oral antihistamines was taken by 52.1% of patients during the up-dosing and 19.7% of patients during the maintenance phase. Taking antihistamines had no effect on the frequency of systemic AE (p=0.11) but large local reactions (LLR) were less frequently seen (OR: 0.74; 95% CI: 0.58-0.96; p=0.02). Aqueous preparations were preferentially used for up-dosing (73.0%) and depot preparations for the maintenance phase (64.5%). The type of venom preparation neither had an influence on the frequency of systemic AE nor on the effectiveness of VIT (p=0.26 and p=0.80, respectively), while LLR were less frequently seen when depot preparations were used (p&lt;0.001). Conclusions: Pretreatment with oral antihistamines during VIT significantly reduces the frequency of LLR but not systemic AE. All venom preparations used were equally effective and did not differ in the frequency of systemic AE.</description><issn>1018-9068</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNotkEtLxDAUhbNQcBxd-QeyFKRjbtPmsZTBx8iAG12HNE00Q5vUpBX6760zru6B-3E4fAjdANmAAM7uD14bvyGS8TO0AgKikISJC3SZ84EQypngK_S6C66bbDA-fGKnzRhTxjHg8cvirJ0dZ6xDi61z1oz-xwabl7_DS4o99n0_hbiwSQ_zFTp3usv2-v-u0cfT4_v2pdi_Pe-2D_vCAGG8aCqoDWFNKZ1oOdPgpCTLOmqpBOCcsVpA3UAltZSgXUWrVhheNa1g4FpH1-j21Duk-D3ZPKreZ2O7Tgcbp6xKIXjFa0nLBb07oSbFnJN1aki-12lWQNTRkjpaUn-W6C9PeV0V</recordid><startdate>20231108</startdate><enddate>20231108</enddate><creator>Arzt-Gradwohl, L</creator><creator>Annik Herzog, S</creator><creator>Aberer, W</creator><creator>Alfaya Arias, T</creator><creator>Antolín-Amérigo, D</creator><creator>Bonadonna, P</creator><creator>Boni, E</creator><creator>Bożek, A</creator><creator>Chełmińska, M</creator><creator>Ernst, B</creator><creator>Frelih, N</creator><creator>Gawlik, R</creator><creator>Gelincik, A</creator><creator>Hawranek, T</creator><creator>Hoetzenecker, W</creator><creator>Jiménez Blanco, A</creator><creator>Kita, K</creator><creator>Kendirlinan, R</creator><creator>Košnik, M</creator><creator>Laipold, K</creator><creator>Lang, R</creator><creator>Marchi, F</creator><creator>Mauro, M</creator><creator>Nittner-Marszalska, M</creator><creator>Poziomkowska-Gęsicka, I</creator><creator>Pravettoni, V</creator><creator>Preziosi, D</creator><creator>Quercia, O</creator><creator>Reider, N</creator><creator>Rosiek-Biegus, M</creator><creator>Ruiz-Leon, B</creator><creator>Schrautzer, C</creator><creator>Serrano, P</creator><creator>Sin, A</creator><creator>Ayşe Sin, B</creator><creator>Stoevesandt, J</creator><creator>Trautmann, A</creator><creator>Vachová, M</creator><creator>Johannes Sturm, G</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20231108</creationdate><title>Influencing factors on the safety and effectiveness of venom immunotherapy</title><author>Arzt-Gradwohl, L ; Annik Herzog, S ; Aberer, W ; Alfaya Arias, T ; Antolín-Amérigo, D ; Bonadonna, P ; Boni, E ; Bożek, A ; Chełmińska, M ; Ernst, B ; Frelih, N ; Gawlik, R ; Gelincik, A ; Hawranek, T ; Hoetzenecker, W ; Jiménez Blanco, A ; Kita, K ; Kendirlinan, R ; Košnik, M ; Laipold, K ; Lang, R ; Marchi, F ; Mauro, M ; Nittner-Marszalska, M ; Poziomkowska-Gęsicka, I ; Pravettoni, V ; Preziosi, D ; Quercia, O ; Reider, N ; Rosiek-Biegus, M ; Ruiz-Leon, B ; Schrautzer, C ; Serrano, P ; Sin, A ; Ayşe Sin, B ; Stoevesandt, J ; Trautmann, A ; Vachová, M ; Johannes Sturm, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1067-b415c06b29f8d76a1f9900183e391177665815b149a991af434d8c74bd861fdf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arzt-Gradwohl, L</creatorcontrib><creatorcontrib>Annik Herzog, S</creatorcontrib><creatorcontrib>Aberer, W</creatorcontrib><creatorcontrib>Alfaya Arias, T</creatorcontrib><creatorcontrib>Antolín-Amérigo, D</creatorcontrib><creatorcontrib>Bonadonna, P</creatorcontrib><creatorcontrib>Boni, E</creatorcontrib><creatorcontrib>Bożek, A</creatorcontrib><creatorcontrib>Chełmińska, M</creatorcontrib><creatorcontrib>Ernst, B</creatorcontrib><creatorcontrib>Frelih, N</creatorcontrib><creatorcontrib>Gawlik, R</creatorcontrib><creatorcontrib>Gelincik, A</creatorcontrib><creatorcontrib>Hawranek, T</creatorcontrib><creatorcontrib>Hoetzenecker, W</creatorcontrib><creatorcontrib>Jiménez Blanco, A</creatorcontrib><creatorcontrib>Kita, K</creatorcontrib><creatorcontrib>Kendirlinan, R</creatorcontrib><creatorcontrib>Košnik, M</creatorcontrib><creatorcontrib>Laipold, K</creatorcontrib><creatorcontrib>Lang, R</creatorcontrib><creatorcontrib>Marchi, F</creatorcontrib><creatorcontrib>Mauro, M</creatorcontrib><creatorcontrib>Nittner-Marszalska, M</creatorcontrib><creatorcontrib>Poziomkowska-Gęsicka, I</creatorcontrib><creatorcontrib>Pravettoni, V</creatorcontrib><creatorcontrib>Preziosi, D</creatorcontrib><creatorcontrib>Quercia, O</creatorcontrib><creatorcontrib>Reider, N</creatorcontrib><creatorcontrib>Rosiek-Biegus, M</creatorcontrib><creatorcontrib>Ruiz-Leon, B</creatorcontrib><creatorcontrib>Schrautzer, C</creatorcontrib><creatorcontrib>Serrano, P</creatorcontrib><creatorcontrib>Sin, A</creatorcontrib><creatorcontrib>Ayşe Sin, B</creatorcontrib><creatorcontrib>Stoevesandt, J</creatorcontrib><creatorcontrib>Trautmann, A</creatorcontrib><creatorcontrib>Vachová, M</creatorcontrib><creatorcontrib>Johannes Sturm, G</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of investigational allergology &amp; clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arzt-Gradwohl, L</au><au>Annik Herzog, S</au><au>Aberer, W</au><au>Alfaya Arias, T</au><au>Antolín-Amérigo, D</au><au>Bonadonna, P</au><au>Boni, E</au><au>Bożek, A</au><au>Chełmińska, M</au><au>Ernst, B</au><au>Frelih, N</au><au>Gawlik, R</au><au>Gelincik, A</au><au>Hawranek, T</au><au>Hoetzenecker, W</au><au>Jiménez Blanco, A</au><au>Kita, K</au><au>Kendirlinan, R</au><au>Košnik, M</au><au>Laipold, K</au><au>Lang, R</au><au>Marchi, F</au><au>Mauro, M</au><au>Nittner-Marszalska, M</au><au>Poziomkowska-Gęsicka, I</au><au>Pravettoni, V</au><au>Preziosi, D</au><au>Quercia, O</au><au>Reider, N</au><au>Rosiek-Biegus, M</au><au>Ruiz-Leon, B</au><au>Schrautzer, C</au><au>Serrano, P</au><au>Sin, A</au><au>Ayşe Sin, B</au><au>Stoevesandt, J</au><au>Trautmann, A</au><au>Vachová, M</au><au>Johannes Sturm, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influencing factors on the safety and effectiveness of venom immunotherapy</atitle><jtitle>Journal of investigational allergology &amp; clinical immunology</jtitle><date>2023-11-08</date><risdate>2023</risdate><volume>35</volume><issue>1</issue><spage>0</spage><epage>0</epage><pages>0-0</pages><issn>1018-9068</issn><abstract>Objectives: The safety profile of venom immunotherapy (VIT) is a relevant issue and considerable differences in safety and efficacy of VIT have been reported. The primary aim of this study was to evaluate the safety of ACE inhibitors and beta-blockers during VIT, which has already been published. For a second analysis, data concerning premedication and venom preparations in relation to systemic adverse events (AE) during the up-dosing phase and the first year of the maintenance phase were evaluated as well as the outcome of field stings and sting challenges. Methods: The study was conducted as an open, prospective, observational, multicenter study. In total, 1,425 patients were enrolled and VIT was performed in 1,342 patients. Results: Premedication with oral antihistamines was taken by 52.1% of patients during the up-dosing and 19.7% of patients during the maintenance phase. Taking antihistamines had no effect on the frequency of systemic AE (p=0.11) but large local reactions (LLR) were less frequently seen (OR: 0.74; 95% CI: 0.58-0.96; p=0.02). Aqueous preparations were preferentially used for up-dosing (73.0%) and depot preparations for the maintenance phase (64.5%). The type of venom preparation neither had an influence on the frequency of systemic AE nor on the effectiveness of VIT (p=0.26 and p=0.80, respectively), while LLR were less frequently seen when depot preparations were used (p&lt;0.001). Conclusions: Pretreatment with oral antihistamines during VIT significantly reduces the frequency of LLR but not systemic AE. All venom preparations used were equally effective and did not differ in the frequency of systemic AE.</abstract><doi>10.18176/jiaci.0967</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1018-9068
ispartof Journal of investigational allergology & clinical immunology, 2023-11, Vol.35 (1), p.0-0
issn 1018-9068
language eng
recordid cdi_proquest_miscellaneous_2887475932
source EZB-FREE-00999 freely available EZB journals
title Influencing factors on the safety and effectiveness of venom immunotherapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A53%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influencing%20factors%20on%20the%20safety%20and%20effectiveness%20of%20venom%20immunotherapy&rft.jtitle=Journal%20of%20investigational%20allergology%20&%20clinical%20immunology&rft.au=Arzt-Gradwohl,%20L&rft.date=2023-11-08&rft.volume=35&rft.issue=1&rft.spage=0&rft.epage=0&rft.pages=0-0&rft.issn=1018-9068&rft_id=info:doi/10.18176/jiaci.0967&rft_dat=%3Cproquest_cross%3E2887475932%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2887475932&rft_id=info:pmid/&rfr_iscdi=true